Clinical Trials: Liver Cancer

Birmingham : University of Alabama at Birmingham Comprehensive Cancer Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

View More »

Birmingham : UAB

Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

Phoenix : Mayo Clinic Arizona

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Phoenix : Mayo Clinic Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Duarte : City of Hope Updated

A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol

Duarte : City of Hope Updated

PHI-64, NCI #8155; A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma

Los Angeles : USC Norris Comprehensive Cancer Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

San Francisco : California Pacific Medical Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

San Francisco : California Pacific Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

View More »

La Jolla : Moores University of California San Diego Cancer Center Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Orange : University of California Irvine Medical Center

TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma

San Francisco : California Pacific Medical Center Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Stanford : Stanford Hospital and Clinics Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Gainesville : University of Florida College of Medicine

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Miami : University of Miami School of Medicine

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

View More »

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

Atlanta : Winship Cancer Institute of Emory University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Atlanta : Piedmont Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Savannah : Memorial Health University Medical Center

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer AHEP0731

Savannah : Memorial Health University Medical Center

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer AHEP0731

Savannah : Memorial Health University Medical Center

Trial NCT01015833 Phase III Randomized Study of Sorefenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) CALGB 80802

Honolulu : Hawaii Medical Center East

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Westwood : University of Kansas Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Louisville : University of Louisville - Surgery

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Louisville : University of Louisville

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

New Orleans : Tulane University Health Services Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

New Orleans : Tulane University Health Services Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

New Orleans : Tulane Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Baltimore : Mercy Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Boston : Massachusetts General Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Boston : Dana-Farber Cancer Institute

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Boston : Beth Israel Deaconess Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Detroit : Henry Ford Health System

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Minneapolis : University of Minnesota Cancer Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Minneapolis : University of Minnesota Medical Center-Fairview

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

St. Louis : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Billings : Billings Clinic Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

New Brunswick : Robert Wood Johnson University Hospital

Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)

New Brunswick : The Cancer Institute of New Jersey

Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)

Albuquerque : University of New Mexico Cancer Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Bronx : Biomedical Research Alliance of New York

Colorectal Liver Metastases Study

Buffalo : Roswell Park Cancer Institute

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

New York : Mount Sinai School of Medicine

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

New York : Mount Sinai School of Medicine

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

New York : Mount Sinai Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Rochester : University of Rochester Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Charlotte : Carolinas Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Cleveland : Experimental Therapeutics Program

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

View More »

Canton : Gabrail Cancer Center Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Portland : OHSU

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Philadelphia : Thomas Jefferson University Hospitals

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Pittsburgh : UPMC Liver Cancer Center

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

View More »

Philadelphia : Thomas Jefferson University

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Pittsburg : UPMC, Montefiore Hospital Liver Cancer Center

Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 In Patients With Primary Liver Cancer

View More »

Houston : UT MD Anderson Cancer Center

4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis

Houston : UT MD Anderson Cancer Center

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Houston : UT MD Anderson Cancer Center

Humanitarian Device Exemption (HDE) Treatment Protocol

Richmond : McGuire D.V.A.M.C. GI (111N)

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Richmond : McGuire D.V.A.M.C. GI (111N)

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seattle : Seattle Cancer Care Alliance / University of Washington

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seattle : Seattle Cancer Center Alliance

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

View More »

Seattle : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Morgantown : West Virginia University - Clinical Trials Research Unit

DEFIBROTIDE2006-05 -Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CRF 312.34)

Buenos Aires : Hospital Universitario Austral
Unidad de Investigación Clínica

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Ciudad Autonoma De Buenos Aires : Hospital Británico de Buenos Aires

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Ciudad Autonoma De Buenos Aires : Hospital Italiano de Buenos Aires

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

ROSARIO Pcia. de Santa Fe : Hospital Provincial del Centenario

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Brisbane : Greenslopes Private Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Camperdown, New South Wales : Royal Prince Alfred Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Clayton : Monash Medical Centre

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Greenslopes, Queensland : Greenslopes Private Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Herston, Queensland : Royal Brisbane and Women's Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Melbourne, Victoria : Austin Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Nedlands, Western Australia : Sir Charles Gairdner Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Prahran, Victoria : The Alfred Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Prahran, Victoria : The Alfred Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Randwick : Prince of Wales Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Randwick, New South Whales : The Prince of Wales Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Linz : Krankenhaus der Elisabethinen Linz GmbH

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

nnsbruck : Medizinische Universität Innsbruck

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Wien : Medizinische Universität Wien

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Brussels : Cliniques Universitaires Saint-Luc

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Bruxelles : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Edegem : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Ghent : University Hospital Ghent

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Ghent : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Kortrijk : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

La Louviere : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Leuven : Universitair Ziekenhuis Gasthuisberg

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Leuven : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Liège : C.H.U. de Liège

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Liège : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

View More »

Bruxelles : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Gent : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Plovdiv : District Dispensary for Oncology Diseases with Inpatient Unit

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Plovdiv : District Dispensary for Oncology Diseases with Inpatient

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Sofia : District Dispensary for Oncology Diseases with Inpatient

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Varna : Inter-district Dispensary for oncology disease with inpatient unit "Dr Marko Markov"

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Varna : Interdistrict Dispensary for Oncological Diseases Dr.M.Marko

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Varna : MHAT Sveta Marina

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Edmonton, Alberta : Cross Cancer Institute

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Halifax, Nova Scotia : Queen Elizabeth II Health Sciences Centre

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Vancouver, British Columbia : British Columbia Cancer Agency

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

View More »

Hamilton : Juravinski Cancer Centre Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Ottawa : Ottawa Hopsital Research Institute Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Santiago : Instituto Nacional del Cancer

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Santiago : Hospital Barros Luco Trudeau

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Temuco : Hospital Regional De Temuco

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Anhui : 1st Hospital Anhui Med. University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : 301 Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : Shan'xi Provincial People's Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : 3rd Xiangya Hospital of C.S.University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : 307 Hospital of PLA

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : Cancer Hospital, Chinese Medical Science Institute

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : Beijing Cancer Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : Beijing Cancer Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : 1st Aff Hosp Xi’an Jiaotong

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : Southwest Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beijing : Beijing Cancer Institute&Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Beijing : 307 Hospital of PLA

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Cheng Du : West China Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Guangdong : Nanfang Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Guangdong : The First Affiliated Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Guangdong : Cancer Hospital Sun Yat-sen University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Guangxi : Guangxi Medical University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Guangzhou : Guangdong General Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Guangzhou : Sun Yat-sen University Cancer Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Hangzhou : Sir Run Run Shaw Hosp Med College of Zhejiang University

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Hubei : Union Hospital of Huazhong University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Hubei : Tongji Hospital of Huazhong University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Hunan Province : Xiangya Hospital of C.S.University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Hunan, : Tumor Hos of Hunan Province

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Jiangsu : Nanjing 81 hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Liaoning : 2nd Aff.Hospital, Dalian Med. University

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Nanjing : Nanjing 81 hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Shan Xi : Tangdu Hospital of 4th Military

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Shanghai : Renji Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Shanghai : Shanghai Eastern Hepatobiliary Surgery Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Sichuan Province : Sichuan Provincial People's

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Tian Jin : Tianjin Cancer Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Zhejiang : Zhejiang Cancer Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Angers : CHU d'Angers

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Bondy : Hôpital Jean Verdier

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Bordeaux : Hôpital Saint André

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Bordeaux : Hôpital Saint André - Bordeaux

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Cédex : Hôpital l'Archet 2

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Clichy : Hôpital Beaujon - Clichy

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Créteil : Hôpital Henri Mondor

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Créteil : Hôpital Henri Mondor -

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

La-Roche-sur-Yon : Centre Hospitalier Départemental- La-Roche-sur-Yon

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Lille : Hôpital Claude Huriez

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Lille : Hôpital Claude Huriez

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Lyon : Hôtel Dieu

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Lyon : Hôtel Dieu - Lyon

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Marseille : CHU La Timone

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Marseille : Hôpital de la Timone -

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Paris : Hôpital Tenon

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Paris : Hôpital Saint-Antoine

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Paris : Hôpital Saint Antoine - Paris

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Pessac : Hopital du Haut Leveque - Pessac

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Rennes : Centre Eugène Marquis

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Toulouse : Hôpital Purpan - Pavillon Dieulafoy

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Vandoeuvre-lès-Nancy : CHU Nancy-Brabois, Hôpital d’Adultes

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Vandoeuvre-lès-Nancy : CHU Brabois - Vandoeuvre-les-Nancy

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Villejuif : Hôpital Paul Brousse

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Villejuif : Hôpital Paul Brousse -

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Berlin : Charite - Unversitatsmedizin Berlin

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Berlin : Charité Universitätsmedizin Berlin Campus Benjamin Franklin

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Düsseldorf : Universitätsklinikum Düsseldorf

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Essen : Universitatsklinikum Essen

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Essen : Medizinische Einrichtungen der Universität Essen

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Frankfurt : Klinikum der Johann Wolfgang Goethe Universität

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Freiburg : Universitatsklinikum Freiburg

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Freiburg : Kliniken und Polikliniken der Albert-Ludwigs-Universität

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Gottingen : Universitatsmedizin Gottingen

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Hamburg : Universitätsklinikrn Hamburg-Eppendorf

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Hannover : Medizinische Hochchule Hannover

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Hannover : Kliniken der Medizinischen Hochschule Hannover

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Homburg : Universitätskliniken des Saarlandes

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Homburg/Saar : Universitatsklinikum des Saarlands

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Köln : Medizinische Einrichtungen der Universität zu Köln

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Magdeburg : Universitatsklinikum Magdeburg AoR

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Mainz : Klinikum der Johannes Gutenberg-Universität MainzI

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Mainz : Klinikum der Johannes-Gutenberg-Universitität

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

München : Klinikum der Universitat Munchen-Grosshadern

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

München : Klinikum rechts der Isar

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Regensburg : Klinikum der Universitat Regensburg

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Regensburg : Klinikum der Universität Regensburg

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Tübingen : Klinikum der Eberhard-Karls-Universität Tübingen

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Hong Kong : Queen Mary Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Beersheva : Soroka University Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Haifa : Rambam Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Petach Tikva : Rabin Medical Center - Beilinson Campus

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Rehovot : Kaplan Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Tel Hashomer : Chaim Sheba Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Zrifin : Assaf Harofeh Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Bari : Sezione Chirurgia Generale e Trapianti di Fegato - Policlinico di Bari

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Benevento : Azienda Ospedaliera "G. Rummo" - Unità Operativa di Oncologia Medica

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Bologna : Azienda Ospedaliera Universitaria di Bologna – Policlinico S. Orsola-Malpighi

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Cagliari : Ospedale A. Businco

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Catania : Azienda Ospedaliera Garibaldi-Nesima - Unità di Epatologia

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Milan : National institute for cancer,

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Milan : Ospedale Fatebenefratelli ed oftalmico,

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Modena : Dipartimento Integrato di Medicina e Specialità Mediche - Unità Complessa di Gastroenterologia

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Napoli : Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale"

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Napoli : Ospedale Fatebenefratelli - Dipartimento Medicina Interna - Centro per le malattie del fegato

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Padova : Azienda Ospedaliera Università di Padova

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Palermo : Azienda Ospedaliera Universitaria "Paolo Giaccone”

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Roma : Policlinico Agostino Gemelli - Universita' Cattolica

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Torino : Ospedale San Giovanni Battista,

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Kyunggi-do : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Seoul : Asan Medical Center

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Seoul : Korea University Guro Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Seoul : Samsung Medical Center

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Seoul : Gangnam Severance Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

View More »

Seoul : Seoul National University Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Seoul : Seoul St. Mary Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Seoul : Severance Hospital, Yonsei University Health System

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Suwon : Ajou University Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Auckland : New Zealand Liver Transplant Unit

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Bydgoszcz : Centrum Onkologii im. Prof. Franciszka Lukaszczyka

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Gdansk : Samodzielny Publiczny Szpital Kliniczny nr 1 ACK AMG

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Gliwice : Centrum Onkologii - Instytut

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Warszawa : Centrum Onkologii - Instytut im. M.Sklodowskiej-Curie

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Barnaul : Altay Oncological Dispensary

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Kazan : Clinical Oncology Dispensary

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Moscow : Russian Scientific Oncology Centre n.a. N.N Blockhin of RAMS

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Nizhniy Novgorod : Privolzhskiy Okruzhnoy Medical Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

St Petersburg : City Clinical Oncology Centre

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Yaroslavl : Clinical Oncology Hospital

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Singapore : Singapore General Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Singapore : National Cancer Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Singapore : Johns Hopkins Singapore IMC

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Johannesburg : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Mayville, Durban : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Newtown Park, Port Elizabeth : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Panorama, Cape Town : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Busan : Pusan National University Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Daegu : Kyungpook National University Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Gyeonggi-do : National Cancer Centre

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Gyeonggi-do : Inje University Ilsan Paik Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Jeonbuk : Chonbuk National University Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seoul : Asan Medical Centre

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seoul : Seoul National University Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seoul : Samsung Medical Centre

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seoul : Gangnam Severance Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Seoul : Severance Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Singapore : National University Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Barcelona : Hospital Clínic i Provincial de Barcelona

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Barcelona : Instituto Catalan de Oncologia

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Barcelona : Hospital Clínic i Provincial de Barcelona

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Lugo : Complejo Hospitalario Xeral Calde

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Madrid : Hospital Infanta Sofía

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Madrid : Hospital Clínico Universitario San Carlos

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Madrid : Hospital Universitario 12 de Octubre

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Madrid : Hospital Infanta Sofía

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Málaga : Hospital Virgen de la Victoria

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Santander : Hospital Universitario "Marqués de Valdecilla"

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Santander : Hospital Universitario "Marqués de Valdecilla"

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Valencia : Hospital Clínico Universitario de Valencia

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Valencia : Hospital Universitario La Fe

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

View More »

Barcelona : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Santander : Updated

A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Goteborg : Sahlgrenska University hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Stockholm : Karolinska University hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Changhua City : Changhua Christian Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Kaohsiung : Chang Gung Memorial Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Kaohsiung City : E-Da Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Kwei-Shan : Chang Gung Memorial Hospital-Linkou Medical Centre

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Taichung : China Medical University Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

View More »

Taichung : Taichung Veterans General Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Tainan : National Cheng Kung University Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Taipei : National Taiwan University Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Taipei : Shin Kong Wu Ho-Su Memorial Hospital

Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy

Taipei City : Taipei Veterans General Hospital

A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

TPE : Chi Mei Hospital, Liouying Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

TPE : National Cheng-Kung University Hospital Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

TPE : National Taiwan University Hospital Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

TPE : Taipei Veterans General Hospital Updated

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Birmingham : CRUK Institute for Cancer Studies

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

Glasgow : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

London : Royal Free Hampstead NHS Trust

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

London : Kings College Hospital

A study to determine whether a drug, sorafenib, is effective in the adjuvant treatment of liver cancer.

London : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Newcastle Upon Tyne : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.

Sheffield : Research Center

This is a Phase III trial designed to evaluate an oral sorafenib combination treatment for advanced liver cancer. Liver cancer patients with disease that is not curable by surgical methods or treatable by local therapy are eligible.